Full-Time

Manager - Cross Systems Program Management

Posted on 11/7/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Operations & Logistics (1)
Requirements
  • Master’s degree & 8+ years of experience in Bio/Pharmaceutical Analytics, Data, and Reporting or Data Engineering
  • Bachelor’s degree & 10+ years of experience in Bio/Pharmaceutical Analytics, Data, and Reporting or Data Engineering
Responsibilities
  • Serve as the business owner for selected field-facing capabilities that rely on multiple platforms and systems and functions to deliver value
  • Manage end-to-end program lifecycle from requirements definition to delivery, adoption, and continuous improvement
  • Partner with Amgen Technology teams, platform owners, and business stakeholders to ensure capabilities are aligned to field and brand needs
  • Design, manage, and optimize cross-system workflows and processes (e.g. sales ops quarter switch process) to ensure seamless execution across teams
  • Proactively identify risks, dependencies, and bottlenecks that could impact delivery and take corrective action
  • Develop and enforce governance structures to ensure consistent data, processes, and integrations across systems and teams
  • Create, own, and continuously improve the Field Systems & Capabilities Product Launch Playbook, ensuring all cross-system dependencies are identified and executed flawlessly
  • Coordinate activities across Field Excellence to ensure readiness for product launches
  • Drive alignment on roles, responsibilities, and timelines for launch activities, ensuring a consistent, repeatable framework for success
  • Measure launch execution effectiveness and recommend improvements for future launches
  • Partner closely with brand teams, field leadership, and business stakeholders to deeply understand business objectives, workflows, and user pain points
  • Translate stakeholder needs into clear, detailed business requirements and partner with Amgen Technology and platform teams to shape technical solutions
  • Act as a trusted advisor by challenging assumptions, recommending best practices, and ensuring that solutions are fit-for-purpose and scalable
  • Build strong, ongoing relationships with stakeholders to continuously refine capabilities, incorporate feedback, and ensure alignment with evolving business strategies
  • Build and manage program roadmaps, ensuring deliverables are on time, within scope, and aligned with strategic priorities
  • Develop and maintain RACI frameworks to clearly define roles and responsibilities across cross-functional teams
  • Support change management, training, and communication efforts to drive adoption of new or enhanced capabilities
  • Define and track KPIs to measure program success, system performance, and field adoption
  • Quantify the business impact of cross-system capabilities, identifying opportunities for expansion, optimization, or decommissioning
  • Continuously benchmark against industry best practices to evolve Amgen’s field systems strategy
  • Establish and maintain clear program and process documentation, including process maps, standards, playbooks, and operating procedures for cross-systems capabilities
  • Create, publish, and enforce standards and best practices to ensure consistency of capability delivery across field teams and to ensure ability to support capability at scale
  • Facilitate alignment sessions with stakeholders to define and agree on standards, ensuring buy-in and adoption of across functions
  • Monitor adherence to governance processes, escalating gaps or risks and driving resolution
  • Continuously refine standards and processes based on feedback, lessons learned, and industry best practices to ensure long-term scalability and sustainability
Desired Qualifications
  • Proven experience managing complex, cross-functional programs that involve multiple systems and stakeholder groups
  • Strong background in program governance, RACI management, and roadmap planning
  • Experience with process optimization and workflow management in enterprise environments
  • Prior experience creating or managing launch playbooks, readiness frameworks, or large-scale program rollouts
  • Familiarity with enterprise platforms supporting field sales (e.g., Veeva CRM, BI tools like Tableau, Incentive Compensation systems, Alignment & Roster Management systems, data integration platforms)
  • Understanding of cross-system dependencies and ability to identify, manage, and resolve integration challenges
  • Experience designing and managing capabilities that span multiple platforms/functions with a focus on consistency, reliability, and scalability
  • Strong ability to translate business needs into technical requirements and ensure alignment across business and Technology teams
  • Skilled communicator who can simplify complex system interactions for business stakeholders
  • Demonstrated ability to influence across functions and drive alignment in ambiguous or complex environments
  • Experience defining KPIs to measure program success, user adoption, and business impact
  • Proven ability to assess program performance and make recommendations to expand, modify, or sunset capabilities based on value delivered
  • Track record of driving continuous improvement and innovation within sales operations or systems programs
  • Strong organizational skills with the ability to manage multiple priorities and deadlines
  • Collaborative mindset with the ability to lead through influence in a matrixed environment
  • Highly proactive problem-solver with attention to detail and accountability
  • Experience working with commercial data sets in Bio/Pharmaceutical industry (e.g. sales, CRM, Patient Hub data, Field Force Effectiveness metrics)
  • Strong understanding of Bio/Pharmaceutical field force effectiveness, commercial field operations processes, and commercial field systems is highly desirable

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE